- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Vor Bio reports positive two-year IgA nephropathy trial data | 1 | Investing.com | ||
| Do | Vor Biopharma: Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy | 1 | GlobeNewswire (USA) | ||
| 06.10. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.09. | Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis | 331 | GlobeNewswire (Europe) | More than 94% of participants achieved a =5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing... ► Artikel lesen | |
| 28.09. | Stifel reiterates Vor Biopharma stock rating on telitacicept potential | 2 | Investing.com | ||
| 23.09. | Vor Biopharma: Telitacicept soll mit dualem Wirkansatz bei Autoimmunerkrankungen punkten | 4 | Investing.com Deutsch | ||
| 09.09. | Vor Biopharma auf dem Citigroup Biopharma-Gipfel: Pipeline-Offensive für Telitacicept | 2 | Investing.com Deutsch | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.09. | Vor Bio auf Wells-Fargo-Konferenz: MG-Medikament zielt auf breiten Wirkvorteil ab | 17 | Investing.com Deutsch | ||
| 04.09. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| 12.08. | Vor Biopharma reports Q2 results | 2 | Seeking Alpha | ||
| 11.08. | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 1.792 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| 11.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 7 | SEC Filings | ||
| 03.08. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 07.07. | Vor Bio appoints David Zaccardelli to board of directors | 1 | Investing.com | ||
| 07.07. | Vor Bio beruft erfahrenen Pharma-Manager David Zaccardelli in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 07.07. | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | 323 | GlobeNewswire (Europe) | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| 07.07. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 08.06. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | Vor Biopharma: Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,450 | +0,62 % | Valneva mit EILMELDUNG: Kaufen Insider bereits massiv? - Jetzt unbedingt lesen! | ||
| CRISPR THERAPEUTICS | 44,075 | +0,48 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 4,890 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,653 | +1,40 % | Ocugen mit KURSALARM: Dieses Kursziel lässt Anleger staunen - Handeln Sie noch heute! | ||
| CLINUVEL | 4,314 | -0,35 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| EDITAS MEDICINE | 2,130 | -1,39 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,840 | -0,71 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,100 | 0,00 % | H.C. Wainwright bekräftigt Verkaufsempfehlung für Sarepta Therapeutics - Kursziel 5 US-Dollar | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,001 | -0,84 % | PacBio, Verily Health Ink Multi-Year Deal to Scale Multi-Read Genomic Data for Biomedical AI | ||
| GERON | 1,021 | 0,00 % | Geron Corporation: Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 | ||
| REDHILL BIOPHARMA | 0,421 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| OCULAR THERAPEUTIX | 5,850 | +0,86 % | H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy | ||
| VERASTEM | 8,900 | -0,11 % | Wainwright reiterates Verastem stock rating on China trial data | ||
| FATE THERAPEUTICS | 1,820 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting | SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Deena Siblock and Conclusion of Consulting Arrangement | Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - SOL GLOBAL INVESTMENTS CORP. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB0) ("SOL Global" or the "Company") announces that Deena Siblock has resigned... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 18,350 Euro und damit +0,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.